{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:50:30Z","timestamp":1775123430073,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.hoc.2017.09.009","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T19:34:30Z","timestamp":1510947270000},"page":"107-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["TAFRO Syndrome"],"prefix":"10.1016","volume":"32","author":[{"given":"Takuro","family":"Igawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2017.09.009_bib1","first-page":"320","article-title":"Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly","volume":"51","author":"Takai","year":"2010","journal-title":"Rinsho ketsueki"},{"issue":"4","key":"10.1016\/j.hoc.2017.09.009_bib2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4","article-title":"Localized mediastinal lymph node hyperplasia resembling thymoma","volume":"9","author":"Castleman","year":"1956","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2017.09.009_bib3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#","article-title":"Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations","volume":"29","author":"Keller","year":"1972","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2017.09.009_bib4","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2017.09.009_bib5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/02841860410002752","article-title":"Fifty years of multicentric Castleman's disease","volume":"43","author":"Waterston","year":"2004","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2017.09.009_bib6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/jcp.2010.082958","article-title":"Multicentric Castleman's disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases","volume":"63","author":"Sato","year":"2010","journal-title":"J\u00a0Clin Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2017.09.009_bib7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman's disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.hoc.2017.09.009_bib8","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.1985.3.9.1202","article-title":"A\u00a0systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients","volume":"3","author":"Frizzera","year":"1985","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2017.09.009_bib9","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","article-title":"Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease","volume":"129","author":"Yu","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2017.09.009_bib10","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V95.4.1406.004k26_1406_1412","article-title":"HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma","volume":"95","author":"Dupin","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2017.09.009_bib11","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/blood.V93.12.4034.412k38_4034_4043","article-title":"Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6","volume":"93","author":"Aoki","year":"1999","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2017.09.009_bib12","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2017.09.009_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1440-1827.2001.01266.x","article-title":"HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease","volume":"51","author":"Suda","year":"2001","journal-title":"Pathol Int"},{"issue":"2","key":"10.1016\/j.hoc.2017.09.009_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2017.09.009_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamadermatol.2013.1552","article-title":"Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue","volume":"149","author":"Fajgenbaum","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2017.09.009_bib16","first-page":"102","article-title":"First European case of TAFRO syndrome associated with Sjogren disease","volume":"2","author":"Abdo","year":"2014","journal-title":"Am J Intern Med"},{"issue":"11","key":"10.1016\/j.hoc.2017.09.009_bib17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.24015","article-title":"Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome","volume":"90","author":"Jain","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2017.09.009_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2162-3619-4-3","article-title":"Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy\u2014a case report","volume":"4","author":"Tedesco","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2017.09.009_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.revmed.2015.04.006","article-title":"Pseudo-adult Still's disease, anasarca, thrombotic thrombocytopenic purpura and dysautonomia: an atypical presentation of multicentric Castleman's disease. Discussion of TAFRO syndrome","volume":"37","author":"Jouvray","year":"2016","journal-title":"Rev Med Interne"},{"issue":"13","key":"10.1016\/j.hoc.2017.09.009_bib20","doi-asserted-by":"crossref","first-page":"e6271","DOI":"10.1097\/MD.0000000000006271","article-title":"A\u00a0life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: the first case report in Latin America","volume":"96","author":"Jose","year":"2017","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.hoc.2017.09.009_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Masaki","year":"2016","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2017.09.009_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00277-016-2875-8","article-title":"Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome","volume":"96","author":"Behnia","year":"2017","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2017.09.009_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1066896908315812","article-title":"Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases","volume":"16","author":"Kojima","year":"2008","journal-title":"Int J Surg Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2017.09.009_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3960\/jslrt.53.57","volume":"53","author":"Kawabata","year":"2013","journal-title":"J\u00a0Clin Exp Hematop"},{"issue":"2","key":"10.1016\/j.hoc.2017.09.009_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3960\/jslrt.54.163","article-title":"Castleman-Kojima disease in a South Asian adolescent","volume":"54","author":"Koduri","year":"2014","journal-title":"J\u00a0Clin Exp Hematop"},{"issue":"3","key":"10.1016\/j.hoc.2017.09.009_bib26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bcmd.2015.06.013","article-title":"Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: a rare case report and review of the literature","volume":"55","author":"Allegra","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.hoc.2017.09.009_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2431-14-139","article-title":"The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease","volume":"14","author":"Kubokawa","year":"2014","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.hoc.2017.09.009_bib28","first-page":"4703608","article-title":"TAFRO syndrome associated with EBV and successful triple therapy treatment: case report and review of the literature","volume":"2016","author":"Simons","year":"2016","journal-title":"Case Rep Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2017.09.009_bib29","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1128\/JVI.73.6.5149-5155.1999","article-title":"Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8","volume":"73","author":"Kellam","year":"1999","journal-title":"J\u00a0Virol"},{"issue":"7","key":"10.1016\/j.hoc.2017.09.009_bib30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/oxfordjournals.annonc.a059281","article-title":"Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group","volume":"6","author":"Siegert","year":"1995","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2017.09.009_bib31","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.09.009_bib32","doi-asserted-by":"crossref","first-page":"42316","DOI":"10.1038\/srep42316","article-title":"Elevated serum interferon gamma-induced protein 10\u00a0kDa is associated with TAFRO syndrome","volume":"7","author":"Iwaki","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.hoc.2017.09.009_bib33","first-page":"121","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","volume":"22","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"10.1016\/j.hoc.2017.09.009_bib34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.hoc.2017.09.009_bib35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2169\/internalmedicine.56.7991","article-title":"Two cases of thrombocytopenia, anasarca, fever, reticulin fibrosis\/renal failure, and organomegaly (TAFRO) syndrome with high serum procalcitonin levels, including the first case complicated with adrenal hemorrhaging","volume":"56","author":"Nara","year":"2017","journal-title":"Intern Med"},{"issue":"8844","key":"10.1016\/j.hoc.2017.09.009_bib36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0140-6736(93)90277-N","article-title":"High serum procalcitonin concentrations in patients with sepsis and infection","volume":"341","author":"Assicot","year":"1993","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.hoc.2017.09.009_bib37","first-page":"2490","article-title":"TAFRO syndrome showing cholangitis on liver biopsy","volume":"57","author":"Nagai","year":"2016","journal-title":"Rinsho Ketsueki"},{"issue":"1","key":"10.1016\/j.hoc.2017.09.009_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3960\/jslrt.53.63","article-title":"Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five cases","volume":"53","author":"Takai","year":"2013","journal-title":"J\u00a0Clin Exp Hematop"},{"issue":"1","key":"10.1016\/j.hoc.2017.09.009_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/imt.15.95","article-title":"Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease","volume":"8","author":"Fajgenbaum","year":"2016","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.hoc.2017.09.009_bib40","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2017.09.009_bib41","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","article-title":"Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease","volume":"21","author":"Casper","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2017.09.009_bib42","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817301491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817301491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:05:41Z","timestamp":1760184341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858817301491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0889858817301491"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2017.09.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAFRO Syndrome","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2017.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}